Mucosal Leishmaniasis
Mostrando 1-12 de 48 artigos, teses e dissertações.
-
1. A randomized, open-label clinical trial comparing the long-term effects of miltefosine and meglumine antimoniate for mucosal leishmaniasis
Abstract INTRODUCTION: The treatment of mucosal leishmaniasis (ML) is difficult due to the toxicity and route of administration of standard drugs. Miltefosine is an oral agent used for leishmaniasis treatment; however, no data exist regarding its use for ML in Brazil. In this study, we aimed to evaluate the efficacy of miltefosine for ML treatment compared
Rev. Soc. Bras. Med. Trop.. Publicado em: 28/03/2019
-
2. Disseminated leishmaniasis: clinical, pathogenic, and therapeutic aspects
Abstract: Disseminated leishmaniasis is a severe and emerging form of American tegumentary leishmaniasis. Disseminated leishmaniasis is defined by the presence of more than 10 polymorphic cutaneous lesions, distributed over more than two noncontiguous parts of the body. Nasal mucosal involvement is observed in almost half of cases. Disseminated leishmaniasis
An. Bras. Dermatol.. Publicado em: 2019-02
-
3. Good response to pentamidine isethionate in a case of Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis that was difficult to treat: Case Report
Abstract In Brazil, meglumine antimoniate is the first drug of choice for mucosal leishmaniasis treatment followed by amphotericin B and pentamidine isethionate. We report the case of a patient with severe mucosal lesions caused by Leishmania (Viannia) braziliensis that were difficult to treat. Over a 14-year period, the patient showed low adherence and thre
Rev. Soc. Bras. Med. Trop.. Publicado em: 17/01/2019
-
4. Complete and de novo assembly of the Leishmania braziliensis (M2904) genome
Leishmania braziliensis is the etiological agent of American mucosal leishmaniasis, one of the most severe clinical forms of leishmaniasis. Here, we report the assembly of the L. braziliensis (M2904) genome into 35 continuous chromosomes. Also, the annotation of 8395 genes is provided. The public availability of this information will contribute to a better k
Mem. Inst. Oswaldo Cruz. Publicado em: 10/12/2018
-
5. Treatment of mucosal leishmaniasis with amphotericin B lipid complex (ABLC)
Rev. Inst. Med. trop. S. Paulo. Publicado em: 08/11/2018
-
6. Mucosal leishmaniasis: the experience of a Brazilian referral center
Abstract INTRODUCTION Pentavalent antimonials (Sbv) are the most commonly used drugs for the treatment of mucosal leishmaniasis (ML), despite their high toxicity and only moderate efficacy. The aim of this study was to report therapeutic responses with different available options for ML. METHODS This study was based on a review of clinical records of 35
Rev. Soc. Bras. Med. Trop.. Publicado em: 2018-06
-
7. American tegumentary leishmaniasis: diagnostic and treatment challenges in a clinical case
ABSTRACT This clinical case presents a patient with a raised and ulcerative lesion with erythematous edges in the mouth, on the lower lip that was unsuccessfully treated as herpes labialis. Clinical data and laboratory tests (Montenegro skin test, indirect immunofluorescence, direct parasite search and polymerase chain reaction) led to the diagnosis of Ameri
Rev. Inst. Med. trop. S. Paulo. Publicado em: 15/02/2018
-
8. Mucosal leishmaniasis: urgent need for more research
Rev. Soc. Bras. Med. Trop.. Publicado em: 2018-02
-
9. Leprosy and American cutaneous leishmaniasis coinfection
Abstract: Brazil is a country with a high prevalence of infectious diseases such as leprosy and leishmaniasis. However, coinfection of these diseases is still poorly understood. We report a case of a patient who presented with lepromatous leprosy and cutaneous-mucosal leishmaniasis at the same period. After clinical, laboratory, and histopathological diagnos
An. Bras. Dermatol.. Publicado em: 2018-02
-
10. American tegumentary leishmaniasis: epidemiological and molecular characterization of prevalent Leishmania species in the State of Tocantins, Brazil, 2011-2015
ABSTRACT Determination of the epidemiological profile of the American tegumentary leishmaniasis (ATL) and identification of Leishmania species that are prevalent in the State of Tocantins were carried out through a retrospective and descriptive study based on data reported in SINAN, in the period from 2011 to 2015. Molecular techniques such as PCR-RFLP and P
Rev. Inst. Med. trop. S. Paulo. Publicado em: 21/12/2017
-
11. Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)
BACKGROUND American tegumentary leishmaniasis (ATL) is a non-lethal parasitic disease that presents with cutaneous (CL) and mucosal (ML) clinical forms. ATL treatment aims at healing the lesions and preventing the development of the late mucosal form. Systemic meglumine antimoniate (MA) therapy with 10-20 mg Sb5+/kg/day is the first choice of treatment. How
Mem. Inst. Oswaldo Cruz. Publicado em: 2017-12
-
12. Final diagnosis of 86 cases included in differential diagnosis of American tegumentary leishmaniasis in a Brazilian sample: a retrospective cross-sectional study
Abstract: Background: Cutaneous leishmaniasis is distributed worldwide, including Brazil. Its several clinical forms need to be distinguished from other dermatoses. Clinical similarities and lack of a gold standard diagnostic tool make leishmaniasis-like lesions a challenging diagnosis. Objectives. To report the final diagnosis of patients primarily suspec
An. Bras. Dermatol.. Publicado em: 2017-10